Binary Prodrug of Dichloroacetic Acid and Doxorubicin with Enhanced Anticancer Activity
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sharma, Amit | - |
dc.contributor.author | Chun, Jieun | - |
dc.contributor.author | Ji, Myung Sun | - |
dc.contributor.author | Lee, Sooyeon | - |
dc.contributor.author | Kang, Chulhun | - |
dc.contributor.author | Kim, Jong Seung | - |
dc.date.accessioned | 2021-11-22T23:40:18Z | - |
dc.date.available | 2021-11-22T23:40:18Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-03-15 | - |
dc.identifier.issn | 2576-6422 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128408 | - |
dc.description.abstract | The inevitable challenge in conventional chemotherapy is to deliver the anticancer drugs to the dense population of tumors cells while minimizing the drug-associated side effects on the normal cells. Cancer cells' preference for glycolysis for energy production is well recognized. Intuitively, taking advantage of such cancer-associated metabolism would be a promising strategy for anticancer drug delivery with minimal side effects. In this investigation, we have designed a binary prodrug PDOX as a sequential drug delivery regimens to realize the combination therapy for cancer. As cancer cells exhibit abrupt metabolism with elevated pyruvate dehydrogenase kinase (PDK) activity, dichloroacetic acid (DCA, a well-known PDK inhibitor) was used in combination with anticancer drug doxorubicin (DOX). The designed molecular prodrug was activated selectively by cancer-associated esterase to deliver DCA and DOX, respectively, and induced synergetic effects. Hence, sequential targeted delivery of molecular prodrug PDOX offers a promising approach to overcome the offside drug toxicity, pharmacokinetics, and biodistribution of individuals and provide an alternative option for cancer treatment. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.subject | TARGETED DRUG-DELIVERY | - |
dc.subject | CANCER-THERAPY | - |
dc.subject | ACTIVATION | - |
dc.subject | APOPTOSIS | - |
dc.title | Binary Prodrug of Dichloroacetic Acid and Doxorubicin with Enhanced Anticancer Activity | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jong Seung | - |
dc.identifier.doi | 10.1021/acsabm.0c00443 | - |
dc.identifier.scopusid | 2-s2.0-85104561811 | - |
dc.identifier.wosid | 000630168200005 | - |
dc.identifier.bibliographicCitation | ACS APPLIED BIO MATERIALS, v.4, no.3, pp.2026 - 2032 | - |
dc.relation.isPartOf | ACS APPLIED BIO MATERIALS | - |
dc.citation.title | ACS APPLIED BIO MATERIALS | - |
dc.citation.volume | 4 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 2026 | - |
dc.citation.endPage | 2032 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Nanoscience & Nanotechnology | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.subject.keywordPlus | TARGETED DRUG-DELIVERY | - |
dc.subject.keywordPlus | CANCER-THERAPY | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordAuthor | theranostic | - |
dc.subject.keywordAuthor | drug delivery | - |
dc.subject.keywordAuthor | doxorubicin | - |
dc.subject.keywordAuthor | cancer | - |
dc.subject.keywordAuthor | fluorescence | - |
dc.subject.keywordAuthor | esterase | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.